HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Nolan
D P
DP
O'Connor
M B
MB
O'Connor
C
C
Moriarty
M
M
O'Leary
A
A
Bergin
C
C
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015331:Cohort Studies; D050171:Dyslipidemias / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy*; D015248:Gemfibrozil / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007494:Ireland / Q000453:epidemiology; D017035:Pravastatin / Q000627:therapeutic use*; D015995:Prevalence; D012189:Retrospective Studies
D019380:Anti-HIV Agents; D000924:Anticholesteremic Agents; D017320:HIV Protease Inhibitors; D000960:Hypolipidemic Agents; D017035:Pravastatin; D015248:Gemfibrozil